Daniel Adelman, MD
Professor
Medicine
School of Medicine

Education & Training

Show all (1) Hide

• M.D. School of Medicine University of California Davis 1983

Publications (57)

Top publication keywords:
Anti-Allergic AgentsIntestine, SmallAntibodies, Anti-IdiotypicImmunoglobulin EDesensitization, ImmunologicAdministration, OralArachisFood HypersensitivityCeliac DiseasePhotochemotherapyAllergensDiet, Gluten-FreePeanut HypersensitivityCommon Variable ImmunodeficiencyPatient Reported Outcome Measures

• Barriers and Solutions to Optimal Food Allergy Prevention, Diagnostic, and Management Strategies.
  The journal of allergy and clinical immunology. In practice 2025 Tilles SA, Adelman DC, Greenhawt M, Irani AM, Lieberman J, Mohideen P, Mustafa SS, Sampson HA, Shaker M, Sinder SB, Virkud YV, Anagnostou A
• Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
  Allergy 2024 Chinthrajah RS, Sindher SB, Nadeau KC, Leflein JG, Spergel JM, Petroni DH, Jones SM, Casale TB, Wang J, Carr WW, Shreffler WG, Wood RA, Wambre E, Liu J, Akinlade B, Atanasio A, Orengo JM, Hamilton JD,…
• Development of the celiac disease symptom diary version 2.1© (CDSD 2.1©) patient-reported outcome measure.
  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2024 Howard K, Adelman D, Ghura S, Acaster S, Clifford S, Kelly CP, Martin SA, Meckley LM, Leffler DA
• Exploratory immunogenicity outcomes of peanut oral immunotherapy: Findings from the PALISADE trial.
  Clinical and translational allergy 2024 Nilsson C, Vereda A, Borres MP, Andersson M, Södergren E, Rudengren M, Smith A, Simon RJ, Ryan R, Fernández-Rivas M, Adelman D, Vickery BP
• Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.
  The Journal of allergy and clinical immunology 2023 Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon LB, Aldridge K, Rosasco M, Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, Farrington M, Robinson D…

Show all (52 more) Hide

• Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2022 Ciaccio C, Goldsobel AB, Anagnostou A, Beyer K, Casale TB, Deschildre A, Fernández-Rivas M, Hourihane JO, Krawiec M, Lieberman J, Scurlock AM, Vickery BP, Smith A, Tilles SA, Adelman DC, Brown KR, …
• Reply.
  The Journal of allergy and clinical immunology 2022 Baker J, Beyer K, du Toit G, Shreffler W, Brown KR, Norval D, Vereda A, Adelman D, Jones SM, Burks W, Casale T
• Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.
  Allergy 2022 Bajzik V, DeBerg HA, Garabatos N, Rust BJ, Obrien KK, Nguyen QA, O'Rourke C, Smith A, Walker AH, Quinn C, Gersuk VH, Farrington M, Jeong D, Vickery BP, Adelman DC, Wambre E
• Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy.
  The Journal of allergy and clinical immunology 2022 Chinthrajah RS, Jones SM, Kim EH, Sicherer SH, Shreffler W, Lanser BJ, Atri N, Babineau DC, Adelman DC, Iqbal A, Limb SL, Rudman Spergel AK, Togias A, Wood RA
• Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials.
  The Journal of allergy and clinical immunology 2021 Brown KR, Baker J, Vereda A, Beyer K, Burks AW, du Toit G, O'B Hourihane J, Jones SM, Norval D, Dana A, Shreffler W, Vickery BP, Casale T, Skeel B, Adelman D
• Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy.
  Allergy 2021 Fernandez-Rivas M, Vereda A, Vickery BP, Sharma V, Nilsson C, Muraro A, Hourihane JO, DunnGalvin A, du Toit G, Blumchen K, Beyer K, Smith A, Ryan R, Adelman DC, Jones SM
• Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy.
  The journal of allergy and clinical immunology. In practice 2021 Nilsson C, Scurlock AM, Dellon ES, Brostoff JM, Pham T, Ryan R, Brown KR, Adelman DC, Aceves SS
• Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis.
  The Journal of allergy and clinical immunology 2021 Patel N, Adelman DC, Anagnostou K, Baumert JL, Blom WM, Campbell DE, Chinthrajah RS, Mills ENC, Javed B, Purington N, Remington BC, Sampson HA, Smith AD, Yarham RAR, Turner PJ
• Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study.
  The journal of allergy and clinical immunology. In practice 2020 Vickery BP, Vereda A, Nilsson C, du Toit G, Shreffler WG, Burks AW, Jones SM, Fernández-Rivas M, Blümchen K, O'B Hourihane J, Beyer K, Anagnostou A, Assa'ad AH, Ben-Shoshan M, Bird JA, Carr TF, Carr …
• Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
  The Lancet. Child & adolescent health 2020 O'B Hourihane J, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, Nilsson C, Ibáñez MD, Deschildre A, Muraro A, Sharma V, Erlewyn-Lajeunesse M, Zubeldia JM, De Blay F, Sauvage CD, Byrne A, …
• Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.
  GastroHep 2019 Syage JA, Green PHR, Khosla C, Adelman DC, Sealey-Voyksner JA, Murray JA
• Oral Immunotherapy for Peanut Allergy.
  The New England journal of medicine 2019 Vickery BP, Hourihane JO, Adelman DC
• AR101 Oral Immunotherapy for Peanut Allergy.
  The New England journal of medicine 2018 PALISADE Group of Clinical Investigators, Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, …
• Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.
  The American journal of gastroenterology 2018 Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP
• Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet.
  Alimentary pharmacology & therapeutics 2017 Mahadev S, Murray JA, Wu TT, Chandan VS, Torbenson MS, Kelly CP, Maki M, Green PH, Adelman D, Lebwohl B
• A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.
  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2017 Leffler DA, Acaster S, Gallop K, Dennis M, Kelly CP, Adelman DC
• A B-Cell Gene Signature Correlates With the Extent of Gluten-Induced Intestinal Injury in Celiac Disease.
  Cellular and molecular gastroenterology and hepatology 2017 Garber ME, Saldanha A, Parker JS, Jones WD, Kaukinen K, Laurila K, Lähdeaho ML, Khatri P, Khosla C, Adelman DC, Mäki M
• No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.
  Gastroenterology 2016 Murray JA, Kelly CP, Green PHR, Marcantonio A, Wu TT, Mäki M, Adelman DC, CeliAction Study Group of Investigators
• Assessing Quality of Life in Patients with Common Variable Immunodeficiency: Why It Matters.
  The journal of allergy and clinical immunology. In practice 2016 Adelman DC, Howard K
• Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.
  Gastroenterology 2014 Lähdeaho ML, Kaukinen K, Laurila K, Vuotikka P, Koivurova OP, Kärjä-Lahdensuu T, Marcantonio A, Adelman DC, Mäki M
• Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
  The Journal of allergy and clinical immunology 2008 Corren J, Shapiro G, Reimann J, Deniz Y, Wong D, Adelman D, Togias A
• A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
  Investigational new drugs 2007 Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM
• Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2004 Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair D, Davancaze T, Adelman D
• Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
  Circulation 2003 Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C, Kramer P, Shear W, Yeung AC, Shunk KA, Chou TM, Popma J, Fitzgerald P, Carroll TE, Forer D, Adelman DC
• Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2002 Chou TM, Woodburn KW, Cheong WF, Lacy SA, Sudhir K, Adelman DC, Wahr D
• Pharmacological approaches.
  Clinical allergy and immunology 2002 Avila PC, Kishiyama JL, Adelman DC
• Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
  Arteriosclerosis, thrombosis, and vascular biology 2001 Chen Z, Woodburn KW, Shi C, Adelman DC, Rogers C, Simon DI
• Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin).
  Circulation 2000 Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, Cooke JP, Yousuf S, DeVault AR, Renschler MF, Adelman DC
• Letter to the editor regarding the use of intravenous immunoglobulin (IVIG) in asthma.
  Clinical immunology (Orlando, Fla.) 1999 Shearer WT, Abramson SL, Adelman DC, Corn B, Cunningham-Rundles C, Kishiyama JL, Richmond W, Shames RS, Sperber K, Stiehm ER, Valacer DJ
• Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects.
  American journal of respiratory and critical care medicine 1999 Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, Ruppel J, Su JQ, Adelman DC
• A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
  Clinical immunology (Orlando, Fla.) 1999 Kishiyama JL, Valacer D, Cunningham-Rundles C, Sperber K, Richmond GW, Abramson S, Glovsky M, Stiehm R, Stocks J, Rosenberg L, Shames RS, Corn B, Shearer WT, Bacot B, DiMaio M, Tonetta S, Adelman DC
• Clinical differences among women with and without self-reported perimenstrual asthma.
  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 1998 Shames RS, Heilbron DC, Janson SL, Kishiyama JL, Au DS, Adelman DC
• Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
  The Journal of allergy and clinical immunology 1997 Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ, Fick RB, Adelman DC
• Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
  Journal of immunology (Baltimore, Md. : 1950) 1997 MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM
• CD45 isoforms on human CD4+ T-cell subsets.
  The Journal of allergy and clinical immunology 1996 Shanafelt MC, Yssel H, Soderberg C, Steinman L, Adelman DC, Peltz G, Lahesmaa R
• Genetic basis of the primary immunodeficiency syndromes.
  The Western journal of medicine 1995 Adelman DC
• Core content outline for clinical and laboratory immunology. AAAI Training Program Directors' Committee.
  The Journal of allergy and clinical immunology 1994 Shearer WT, Adelman DC, Huston DP, Engler RJ, Gupta S, Ledford DK, Lopez M, Du Buske LM
• The cross-reactivity and immunology of beta-lactam antibiotics.
  Drug safety 1994 Kishiyama JL, Adelman DC
• Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide.
  The Journal of allergy and clinical immunology 1993 Hassner A, Lau MS, Goetzl EJ, Adelman DC
• 13-cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency.
  The Journal of allergy and clinical immunology 1991 Adelman DC, Yen TY, Cumberland WG, Sidell N, Saxon A
• Biologic response modifiers in primary immunodeficiency disorders.
  Annals of internal medicine 1991 Hassner A, Adelman DC
• Penicillin allergy.
  The Western journal of medicine 1991 Adelman D
• Molecular characteristics of the cellular receptor for vasoactive intestinal peptide.
  Transactions of the Association of American Physicians 1991 Goetzl EJ, Hassner A, Cheng PP, Robichon A, Adelman DC, Sreedharan SP
• Neuropeptides, mast cells and allergy: novel mechanisms and therapeutic possibilities.
  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1990 Goetzl EJ, Cheng PP, Hassner A, Adelman DC, Frick OL, Sreedharan SP
• Elevated serum interleukin-6 associated with a failure in B cell differentiation in common variable immunodeficiency.
  The Journal of allergy and clinical immunology 1990 Adelman DC, Matsuda T, Hirano T, Kishimoto T, Saxon A
• Neuroimmunology.
  Advances in immunology 1990 Goetzl EJ, Adelman DC, Sreedharan SP
• Acute respiratory emergencies in emergency treatment of the injured athlete.
  Clinics in sports medicine 1989 Adelman DC, Spector SL
• Fixed cutaneous eruptions to seminal-plasma challenge: a case report.
  Fertility and sterility 1988 Best CL, Walters C, Adelman DC
• Imipenem cross-reactivity with penicillin in humans.
  The Journal of allergy and clinical immunology 1988 Saxon A, Adelman DC, Patel A, Hajdu R, Calandra GB
• Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency.
  The Journal of experimental medicine 1988 Sherr E, Adelman DC, Saxon A, Gilly M, Wall R, Sidell N
• Recurrent bacterial infections and cellulitis in a 29-year-old woman with a history of hypogammaglobulinemia.
  Annals of allergy 1987 Adelman DC, Saxon A
• Immediate hypersensitivity reactions to beta-lactam antibiotics.
  Annals of internal medicine 1987 Saxon A, Beall GN, Rohr AS, Adelman DC